anti-Desmoplakin 1/2 mouse monoclonal, DP1 + 2-2.15, liquid, purified, sample

Liquid

1 ml (50 µg/ml)

Lyophilized

50 µg

Liquid

200 µl (50 µg/ml)

Cat. No. 690003S

Prices excl. VAT

Available, delivery time: 1-7 days

€96.00*

Datasheet

Key Features

Mouse monoclonal
Suitable for ICC/IF, IHC and WB
Reacts with bovine, chicken, human, mouse, rat
Isotype: IgG1

Product description

Quantity	200 µl
Antibody Type	Monoclonal
Host	Mouse
Isotype	IgG1
Conjugate	Unconjugated
Application	ICC/IF, IHC, WB
Purification	Affinity chromatography
Reactivity	Bovine, Chicken, Human, Mouse, Rat
Storage	Short term at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles
Intended use	Research use only
Clone	DP1 + 2-2.15
Immunogen	Bovine desmoplakin 1 + 2
Concentration	50 µg/ml (10 µg)
Formulation	PBS pH 7.4 with 0.09% sodium azide and 0.5% BSA
UniprotID	A0A3Q1MR22 (Bovine), P15924 (Human), E9Q557 (Mouse), F1LMV6 (Rat)
Synonym	Desmoplakin, DP, 250/210 kDa paraneoplastic pemphigus antigen, DSP

Applications

Tested applications	Tested dilutions
Immunocytochemistry (ICC)/ Immunofluorescence (IF)	Assay dependent
Immunohistochemistry (IHC) - frozen	1:10-1:50 (1-5 µg/ml)
Immunohistochemistry (IHC) - paraffin	1:10-1:50 (1-5 µg/ml, microwave treatment recommended)
Western Blot (WB)	Assay dependent

Background

DP1 + 2-2.15 shows distinct punctate membrane staining of different epithelia. Tumors specifically detected: primary and metastatic carcinoma and meningioma. Polypeptides reacting: Desmoplakin 1 and 2 (Mr 250,000 and 215,000).

The epitope recognized by clone DP1 + 2-2.15 is mapped to the N-terminus of the rod domain (Bornslaeger, E. A., 1996).

Bornslaeger, E. A. Breaking the connection: displacement of the desmosomal plaque protein desmoplakin from cell-cell interfaces disrupts anchorage of intermediate filament bundles and alters intercellular junction assembly. J. Cell Biol. 134, 985–1001 (1996).

References/Publications (26)

Publication

Species

Application

Publication Dietrich, N. et al. Adhesion of pancreatic tumor cell clusters by desmosomal molecules enhances early liver metastases formation. Sci Rep 14, 18189 (2024).

Species human, mouse

Application WB

Publication Shoykhet, M., Waschke, J. & Yeruva, S. Cardiomyocyte cohesion is increased after ADAM17 inhibition. Front Cell Dev Biol 11, (2023).

Species mouse

Application WB

Publication Shoykhet, M., Waschke, J. & Yeruva, S. Cardiomyocyte cohesion is increased after ADAM17 inhibition. Front Cell Dev Biol 11, (2023).

Species mouse

Application ICC-IF

Publication Shoykhet, M. et al. EGFR inhibition leads to enhanced desmosome assembly and cardiomyocyte cohesion via ROCK activation. JCI Insight 8, (2023).

Species mouse

Application WB

Publication Yeruva, S. et al. Cholinergic signaling impairs cardiomyocyte cohesion. Acta Physiologica 236, (2022).

Species mouse

Publication Cabrera-Borrego, E. et al. Heterozygous arrhythmogenic cardiomyopathy-desmoplakin mutation carriers exhibit a subclinical cutaneous phenotype with cell membrane disruption and lack of intercellular adhesion. J Clin Med 10, (2021).

Species human

Application IHC

Publication Ding, X. et al. Epidermal mammalian target of rapamycin complex 2 controls lipid synthesis and filaggrin processing in epidermal barrier formation. Journal of Allergy and Clinical Immunology 145, 283-300.e8 (2020).

Species mouse

Application IHC(paraffin), WB

Publication Schinner, C. et al. Stabilization of desmoglein-2 binding rescues arrhythmia in arrhythmogenic cardiomyopathy. JCI.Insight. 5, (2020)

Species mouse

Application WB

Publication Dedeić, Z. et al. Cell autonomous role of iASPP deficiency in causing cardiocutaneous disorders. Cell.Death.Differ. 25, 1289-1303 (2018)

Species mouse

Application ICC-IF

Publication Shafraz, O. et al. E-cadherin binds to desmoglein to facilitate desmosome assembly. Elife. 7, (2018).

Species human

Application ICC-IF

Publication Wallace, L., Roberts-Thompson, L. & Reichelt, J. Deletion of K1/K10 does not impair epidermal stratification but affects desmosomal structure and nuclear integrity. J. Cell Sci. 125, 1750–1758 (2012).

Species mouse

Application IHC (frozen)

Publication Bosch, F. X., Andl, C., Abel, U. & Kartenbeck, J. E-cadherin is a selective and strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-cadherin with desmosomal components. Int. J. cancer 114, 779–90 (2005).

Species human

Application IHC (frozen)

Publication Miravet, S. et al. Tyrosine Phosphorylation of Plakoglobin Causes Contrary Effects on Its Association with Desmosomes and Adherens Junction Components and Modulates ␤-Catenin-Mediated Transcription. Mol. Cell. Biol. 23, 7391–7402 (2003).

Species human

Application WB

Publication Weiske, J. et al. The Fate of Desmosomal Proteins in Apoptotic Cells. J. Biol. Chem. 276, 41175–41181 (2001).

Species human

Application WB,ICC-IF

Publication Hatzfeld, M., Haffner, C., Schulze, K. & Vinzens, U. The Function of Plakophilin 1 in Desmosome Assembly and Actin Filament Organization. J. Cell Biol. 149, 209–222 (2000)

Species human

Application ICC-IF

Publication Moll, I., Houdek, P., Schäfer, S., Nuber, U. & Moll, R. Diversity of desmosomal proteins in regenerating epidermis: immunohistochemical study using a human skin organ culture model. Arch. Dermatol. Res. 291, 437–46 (1999).

Species human

Application IHC (frozen)

Publication Moll, I., Kurzen, H., Langbein, L., Erner, W. & Franke, W. The Distribution of the Desmosomal Protein, Plakophilin 1, in Human Skin and Skin Tumors. J. Invest. Dermatol. 108, 139–146 (1997).

Species human

Application IHC (frozen)

Publication Bornslaeger, E. A. Breaking the connection: displacement of the desmosomal plaque protein desmoplakin from cell-cell interfaces disrupts anchorage of intermediate... J. Cell Biol. 134, 985–1001 (1996).

Application epitope mapping

Publication Owaribe, K., Nishizawa, Y. & Franke, W. W. Isolation and characterization of hemidesmosomes from bovine corneal epithelial cells. Exp. Cell Res. 192, 622–30 (1991).

Species bovine

Application IHC (frozen)

Publication Owaribe, K. et al. The hemidesmosomal plaque. I. Characterization of a major constituent protein as a differentiation marker for certain forms of epithelia. Differentiation. 45, 207–20 (1990).

Species rat

Application IHC (frozen)

Publication Rungger-Brandle, E., Achtstatter, T. & Franke, W. W. An epithelium-type cytoskeleton in a glial cell: Astrocytes of amphibian optic nerves contain cytokeratin filaments and are connected by desmosomes. J. Cell Biol. 109, 705–716 (1989).

Species R. ridibunda

Application IHC (frozen)

Publication Moll, I; Heid, H; Moll, R. Cytokeratin analysis of pilomatrixoma: changes in cytokeratin-type expression during differentiation. J. Invest. Dermatol. 91, 251–7 (1988).

Species human

Application IHC (frozen)

Publication Franke, W. W. & Moll, R. Cytoskeletal components of lymphoid organs. I. Synthesis of cytokeratins 8 and 18 and desmin in subpopulations of extrafollicular reticulum cells of human lymph nodes, tonsils, and spleen. Differentiation. 36, 145–63 (1987).

Species human

Application IHC (frozen)

Publication Dockhorn-dworniczak, b. et al. patterns of expression of cytoskeletal proteins in human thyroid gland and thyroid carcinomas. differentiation. 35, 53–71 (1987).

Species human

Application IHC (frozen)

Publication Achtstätter, T. et al. Expression of glial filament protein (GFP) in nerve sheaths and non-neural cells re-examined using monoclonal antibodies, …. Differentiation 31, 206–227 (1986)

Species human

Application IHC (frozen)

Publication Cowln, P., Kapprell, H.-P. & Franke, W. W. The Complement of Desmosomal Plaque Proteins in Different Cell Types. J. Cell Biol. 101, 1442–1454 (1985)

Species human

Application IHC (frozen),IEM

Downloads

File

Category

Size

Filetype

File IHC mouse antibody

Category Protocol

Size 167.19 KB

Filetype pdf

File Immunofluorescence Protocol

Category Protocol

Size 178.25 KB

Filetype pdf

Datasheet

MSDS

FAQs

The concentration of unpurified supernatant, ascites, unpurified guinea pig serum and unpurified rabbit serum is not determined.
The concentration of purified antibodies is mentioned on the datasheet.
For prediluted antibodies the concentration may vary from lot to lot. The concentration of these antibodies is not mentioned on the datasheet and can be requested at support@progen.com.

Most of our purified mouse antibodies contain 0.5% BSA as stabilizer. If BSA was added to the antibody solution, it is stated in the datasheet.
The supernatant format contains FCS proteins from cell culture medium supplemented with FCS.
The serum antibodies contain other proteins present in serum.

Please find the solvent for reconstitution and the amount of liquid for reconstitution on the antibody datasheet. The buffer formulation after reconstitution is also mentioned in the datasheet.

PROGEN offers different formats for mouse monoclonal antibodies. Different antibodies may not be offered in each format, the following are all possible formats:

Supernatant and supernatant concentrate: This format contains hybridoma cell culture supernatant. The antibody is not purified and the antibody concentration is not determined. The antibody concentration may vary from lot to lot. Therefore we recommend to titrate the optimal concentration for the application used for each new lot.
Lyophilized, purified: This format contains purified antibody in lyophilized form. The reconstitution of this antibody is described in the datasheet. The buffer composition after reconstitution is also mentioned on the datasheet.
Liquid, purified: This format contains purified antibody in liquid format. The concentration is mentioned on the datasheet.
Prediluted, purified: This format contains purified antibody in liquid format. Most antibodies in this format are diluted to be ready-to-use for IHC with standard tissue. But some antibodies of this format need further dilution for IHC. This is mentioned on the datasheet.

Lyophilized antibodies can be stored at 2-8°C until expiration.
Most of our liquid antibodies and reconstituted lyophilized antibodies may be stored for short term storage (up to 3 month) at 2-8°C. For long term storage we recommend to store the antibody at -20°C in aliquots. Please avoid freeze and thaw cycles.
Most of our conjugated antibodies should be stored at 2-8°C.
The individual storage conditions are mentioned on the datasheet.

The expiration date of our antibodies is indicated on the product label.

We offer bulk amounts starting from 1 mg for many of our mouse monoclonal or recombinant antibodies. Please contact us for further information or use the “bulk button” on the product page.

Most of our antibodies contain 0.09% sodium azide as preservative. If a preservative is added, it is mentioned in the datasheet.

The optimal antibody dilution for your specific protocol and application needs to be titrated in your lab with your equipment and sample. The optimal dilution may vary between protocols and samples. A good dilution for starting the titration is the dilution mentioned in the datasheet. If the sample needs a specific treatment (eg. Antigen retrieval for IHC on FFPE sections) this should also be mentioned on the antibody datasheet.

PROGEN antibodies are shipped at ambient temperature. The antibodies are stable at ambient temperature for the shipment period. Please store the antibodies as indicated in the datasheet upon arrival.

Wash cells 1x with PBS (37°C).
Fix in ice-cold (pre-cooled to -20°C) methanol (5-10 min), followed by ice-cold acetone (30-60 sec).
Optional: to enhance the epitope accessibility incubate for 5 min with 0.1% Triton-X100 in PBS.
Let air dry.
Block with the serum of the species in which the secondary antibody was raised for 30 min at RT.
Incubate with primary antibody overnight at 4°C.
Wash 3x with PBS at RT.
Incubate 1 h with fluorochrome-conjugated secondary antibody.
Wash 2x with PBS.
Embed in mounting medium.

Homogenization of tissue in PBS (supplemented with protease inhibitors).
Centrifugation at 10E4 x g.
Optional: treat pellet with DNase.
Resuspend pellet in detergent buffer (e.g. 1% Triton X-100), stir for 1 h at 2-8°C.
Centrifugation at 10E4 x g.
Resuspend pellet in high salt buffer (with 1.5 M KCl), stir for 1 h at 2-8°C.
Centrifugation at 10E4 x g.
Resuspend pellet in low salt buffer (e.g. 50 mM NaCl), stir for 30 min at 2-8°C.
Centrifugation at 10E4 x g: pellet contains raw cytoskeletal fraction.

Transfer from a low concentration acrylamide gel (e.g. 8%).
Reduce the methanol concentration of the transfer buffer (limit is 50% of the routine concentration 20% methanol).
Use the wet transfer method and transfer at least 4 h (or better overnight) at 100-200 mA.
In order to prevent the accumulation of gas bubbles, stir the transfer buffer continuously during the transfer (e.g. with a magnetic stirrer).
If possible use a cytoskeletal preparation of your material to be analyzed (in the case of cultured cells additionally DNase treatment) rather than whole cell lysate.
As a general rule we would like to recommend loading that much protein into one gel lane that the intermediate filament polypeptides (in the 40-60 kD range) can be readily detected in a control gel stained with Coomassie blue.

Contact

Need more product information?

Learn more

anti-Desmoplakin 1/2 mouse monoclonal, DP1 + 2-2.15, liquid, purified, sample

What is the concentration of my antibody?

Do the antibodies contain any other proteins?

How do I reconstitute lyophilized antibodies from PROGEN?

What is the difference between the mouse monoclonal antibody formats?

How should I store the PROGEN antibodies?

What is the shelf life of the PROGEN antibodies?

Can I order bulk amounts of a PROGEN antibody?

Do the PROGEN antibodies contain a preservative?

How can I find the optimal antibody dilution for my experiment?

How are PROGEN antibodies shipped?

Protocol for ICC with Desmoplakin 1/2 antibodies

Protocol for cytoskeletal protein preparation

Tips for WB with desmosomal protein antibodies